JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias
Sang-Kyu Kim, Deborah A Knight, Lisa R Jones, Stephin Vervoort, Ashley P Ng, John F Seymour, James E Bradner, Michaela Waibel, Lev Kats, Ricky W Johnstone
Genes and Develpment | COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT | Published : 2018
Related Projects (1)
Awarded by NHMRC project
Awarded by NHMRC Program
We thank Novartis for generously supplying ruxolitinib and CHZ868; Dr. Johannes Zuber and Dr. Geoff Matthews for assistance with shRNA technology; Viki Milovac, Sophie Curcio, and Ralph Rossi for flow cytometry assistance; and Eva Vidacs, Lauren Dawes, and Kat Papastratos for animal husbandry. This work was supported by a project grant from the Cancer Council Victoria (to M.W. and R.W.J.), a Cancer Therapeutics Cooperative Research Centre PhD Top-Up Scholarship and Melbourne International Research Scholarship (to S.-K.K.), a C.J. Martin Fellowship from the National Health and Medical Research Council (NHMRC; to L.K.), NHMRC project grants (APP1122783 and APP 1060179 to A.P.N.), NHMRC Program grants (454569 to R.W.J., and 1113577 to A.P.N.), a NHMRC Senior Principal Research Fellowship (R.W.J.), and The Kids' Cancer Project (S.V. and R.W.J.).